HomeCompareBOIRF vs MAIN

BOIRF vs MAIN: Dividend Comparison 2026

BOIRF yields 4.58% · MAIN yields 6.91%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MAIN wins by $42.86M in total portfolio value
10 years
BOIRF
BOIRF
● Live price
4.58%
Share price
$30.00
Annual div
$1.37
5Y div CAGR
-6.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.7K
Annual income
$277.87
Full BOIRF calculator →
MAIN
Main Street Capital Corporation
● Live price
6.91%
Share price
$52.96
Annual div
$3.66
5Y div CAGR
72.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$42.89M
Annual income
$35,818,348.00
Full MAIN calculator →

Portfolio growth — BOIRF vs MAIN

📍 MAIN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBOIRFMAIN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BOIRF + MAIN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BOIRF pays
MAIN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BOIRF
Annual income on $10K today (after 15% tax)
$389.02/yr
After 10yr DRIP, annual income (after tax)
$236.19/yr
MAIN
Annual income on $10K today (after 15% tax)
$587.42/yr
After 10yr DRIP, annual income (after tax)
$30,445,595.80/yr
At 15% tax rate, MAIN beats the other by $30,445,359.61/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BOIRF + MAIN for your $10,000?

BOIRF: 50%MAIN: 50%
100% MAIN50/50100% BOIRF
Portfolio after 10yr
$21.46M
Annual income
$17,909,312.94/yr
Blended yield
83.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MAIN right now

BOIRF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
4.4
Piotroski
6/9
MAIN
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$65.25
+23.2% upside vs current
Range: $60.00 — $70.00
Altman Z
1.7
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BOIRF buys
0
MAIN buys
0
No recent congressional trades found for BOIRF or MAIN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBOIRFMAIN
Forward yield4.58%6.91%
Annual dividend / share$1.37$3.66
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-6.9%72.7%
Portfolio after 10y$24.7K$42.89M
Annual income after 10y$277.87$35,818,348.00
Total dividends collected$3.5K$41.85M
Payment frequencyquarterlymonthly
SectorStockBDC
Analyst consensusBuyHold

Year-by-year: BOIRF vs MAIN ($10,000, DRIP)

YearBOIRF PortfolioBOIRF Income/yrMAIN PortfolioMAIN Income/yrGap
1← crossover$11,126$426.09$12,434$1,193.51$1.3KMAIN
2$12,317$412.48$16,255$2,280.05$3.9KMAIN
3$13,577$397.33$22,851$4,580.08$9.3KMAIN
4$14,908$381.06$35,577$9,892.59$20.7KMAIN
5$16,316$364.08$63,653$23,664.70$47.3KMAIN
6$17,805$346.69$136,601$65,054.52$118.8KMAIN
7$19,380$329.18$368,044$214,504.02$348.7KMAIN
8$21,049$311.76$1,301,668$887,987.40$1.28MMAIN
9$22,817$294.61$6,288,483$4,825,407.47$6.27MMAIN
10$24,692$277.87$42,886,603$35,818,348.00$42.86MMAIN

BOIRF vs MAIN: Complete Analysis 2026

BOIRFStock

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and Sédatif PC to treat anxiety and emotional, and minor sleep disorders. The company's homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; and Homéovox for vocal disorders. In addition, it provides dietary supplement; Dermoplasmine stick, baume, and mousse to treat dry lips and skin; Mag' Nuit, a formula to fall asleep; Arnitrosium for joint pain; Castor Equi Boiron ointment for treatment of cracked skin; and Storinyl, a syrup to treat colds. Further, it offers herbal medicines, such as Canephron to increase the amount of urine and to improve urinary elimination; moisturizing baby milk; and medical devices, including a range of COVID self-tests and rapid antigenic tests. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.

Full BOIRF Calculator →

MAINBDC

Main Street Capital Corporation is a business development company specializes in equity capital to lower middle market companies. The firm specializing in recapitalizations, management buyouts, refinancing, family estate planning, management buyouts, refinancing, industry consolidation, mature, later stage emerging growth. The firm also provides debt capital to middle market companies for acquisitions, management buyouts, growth financings, recapitalizations and refinancing. The firm seeks to partner with entrepreneurs, business owners and management teams and generally provides one stop financing alternatives within its lower middle market portfolio. It prefers to invest in air freight and logistics, auto components, building products, chemicals, commercial services, computers, construction and engineering, consumer finance, consumer services, electronic equipment, energy equipment and services, financial services, health care equipment, health care providers, hotels, restaurants, and leisure, internet software and services, IT Services, machinery, oil, gas and consumable fuels, paper and forest products, professional and industrial services, road and rail, software, specialty retail, telecommunication, consumer discretionary, energy, materials, technology, and transportation. The firm typically invests in lower middle market companies generally with annual revenues between $5 million and $300 million. It prefers to invest in ranging between $2 million and $75 million in equity investment and enterprise value in ranging between $3 million and $20 million. The firm typically prefers to invest in the range of $5 million and $50 million per transaction in debt investment value and in the range of $1 million and $20 million in annual EBITDA. The firm's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies. It takes 5 percent minority and up to 50 percent majority equity investments. Main Street Capital Corporation was founded in 2007 and is based in Houston, Texas with an additional office in Chojnów, Poland.

Full MAIN Calculator →
📬

Get this BOIRF vs MAIN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BOIRF vs SCHDBOIRF vs JEPIBOIRF vs OBOIRF vs KOBOIRF vs ARCCBOIRF vs HTGCBOIRF vs GBDCBOIRF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.